Select another
Cluster
 

In vitro multi-target screening platform to identify novel CNS regenerative drugs for commercial development

Type : Technology offer

Country : Luxembourg

A Luxembourgish company has pioneered the development of a new class of compounds having the capacity to induce differentiation of neural stem cells into neurons and possessing anti-inflammatory neuroprotective activities. These pro-regenerative compounds are being developed as disease-modifying drugs for neurodegenerative disorders such as Parkinson's disease and Multiple Sclerosis. The Company is interested in collaboration with partners coming from Academia or Industry.

Deadline: 7 July 2012

More info

Back to all technology offers